| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.21B | 10.41B | 13.30B | 14.40B | 11.30B | 7.39B |
| Gross Profit | 10.85B | 10.49B | 12.16B | 14.37B | 8.50B | 5.62B |
| EBITDA | 3.17B | 3.11B | 5.06B | 6.77B | 4.79B | 2.76B |
| Net Income | 1.58B | 1.62B | 3.19B | 3.83B | 1.88B | 666.06M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 23.93B | 20.56B | 17.55B | 15.31B | 14.32B |
| Cash, Cash Equivalents and Short-Term Investments | 2.43B | 2.55B | 3.95B | 2.31B | 695.11M | 555.29M |
| Total Debt | 0.00 | 2.35B | 978.23M | 693.85M | 9.00B | 9.06B |
| Total Liabilities | -18.64B | 5.29B | 3.54B | 3.24B | 12.69B | 13.60B |
| Stockholders Equity | 18.64B | 18.64B | 17.02B | 14.31B | 2.62B | 723.83M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -873.38M | 1.71B | 3.96B | 2.18B | 1.09B |
| Operating Cash Flow | 0.00 | 1.76B | 3.79B | 4.96B | 3.15B | 1.19B |
| Investing Cash Flow | 0.00 | -2.46B | -3.07B | -2.90B | -1.10B | -17.52M |
| Financing Cash Flow | 0.00 | 649.80M | -325.69M | -2.12B | -2.24B | -1.10B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ₹70.14B | 11.03 | ― | 3.68% | -7.53% | 42.74% | |
68 Neutral | ₹69.34B | 10.38 | ― | 2.80% | 15.25% | 26.49% | |
64 Neutral | ₹104.06B | 39.00 | ― | 0.15% | 24.25% | 96.45% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
60 Neutral | ₹32.82B | 19.51 | ― | 0.19% | 21.67% | 25.86% | |
59 Neutral | ₹34.96B | 23,338.24 | ― | 3.11% | 10.35% | ― | |
58 Neutral | ₹67.72B | 39.64 | ― | 0.78% | -3.15% | -22.30% |
Archean Chemical Industries Ltd. has entered into a Rs 150 crore unsecured loan agreement with its wholly owned subsidiary Neun Infra Private Ltd. to provide interim funding support for its semiconductor-focused activities. Neun Infra is the holding company of SiCSem Private Ltd., which has received approval under the India Semiconductor Mission to set up a compound semiconductor and ATMP manufacturing facility, and the funding will enable procurement of long-lead machinery, equipment, and related project expenditures, as well as silicon carbide R&D in collaboration with IIT Bhubaneswar, ahead of the formal fiscal support agreement with the Government of India. The loan, part of a sanctioned Rs 300 crore facility with Rs 157 crore outstanding, carries a 7.5% annual interest rate, is repayable over five years starting in FY 2029-30, and is structured as an arm’s-length related-party transaction, underscoring Archean Chemical’s strategic push into semiconductor manufacturing and its intent to maintain project timelines under the national mission framework.
Archean Chemical Industries Ltd. announced the release of the transcript for its earnings call, which followed the announcement of its financial results for the quarter and half-year ending September 30, 2025. This release is part of the company’s compliance with regulatory requirements, and the transcript is available on the company’s website. The earnings call featured key management personnel discussing the financial performance, which is crucial for stakeholders to assess the company’s operational and financial health.
Archean Chemical Industries Ltd. announced the approval of its un-audited financial results for the quarter and half-year ending September 30, 2025, during a board meeting. The results, reviewed by the audit committee, show a profit after tax of Rs. 3,846.27 lakhs for the quarter, indicating a strong financial performance. This announcement underscores the company’s solid market position and operational efficiency, which are likely to have positive implications for stakeholders.
Archean Chemical Industries Limited has announced the schedule for its upcoming earnings call, which will discuss the company’s financial results for the quarter and half-year ending September 30, 2025. The call is scheduled for November 18, 2025, at 11:30 AM IST, and will provide insights into the company’s operational and financial performance, potentially impacting its market positioning and stakeholder interests.